The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Lilly; Merck; MSD; Pfizer; Proacta
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Lilly; MSD; Proacta
Phase I/III trial of atezolizumab with carboplatin and etoposide in ES-SCLC in first-line setting (IMpower133).
 
Leora Horn
Honoraria - Biodesix
Consulting or Advisory Role - Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; Genentech; Lilly; Merck; Xcovery
Research Funding - AstraZeneca (Inst)
 
Aaron Scott Mansfield
Consulting or Advisory Role - Celgene; Genentech (Inst); Trovagene
Travel, Accommodations, Expenses - Celgene; Rockpointe; Trovagene
 
Martin Reck
No Relationships to Disclose
 
Tony Mok
Employment - The Chinese University of Hong Kong
Leadership - Sanomics Limited
Stock and Other Ownership Interests - Sanomics Limited
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Lilly; Merck Sharp & Dohme; Novartis; Pfizer; Roche/Genentech
Consulting or Advisory Role - ACEA Biosciences; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Cirina; Clovis Oncology; geneDecode; Ignyta; Lilly; Merck Serono; Merck Sharp & Dohme; Novartis; Oncogenex; Pfizer; Roche/Genentech; SFJ Pharmaceuticals Group; Vertex
Research Funding - AstraZeneca (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); Eisai (Inst); Merck Sharp & Dohme (Inst); Novartis (Inst); Pfizer (Inst); Roche (Inst); SFJ Pharmaceuticals Group (Inst); Taiho Pharmaceutical (Inst)
 
Alexander I. Spira
Honoraria - ARIAD; Clovis Oncology; Novartis; Roche
Consulting or Advisory Role - ARIAD; Clovis Oncology; Roche/Genentech
Research Funding - Abbvie (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Boehringer Ingelheim (Inst); Clovis Oncology (Inst); Ignyta (Inst); Incyte (Inst); MedImmune (Inst); Newlink Genetics (Inst); Novartis (Inst); Roche (Inst)
Expert Testimony - Novartis
Travel, Accommodations, Expenses - ARIAD; Clovis Oncology; Roche
 
Xiongwen Tang
Employment - Roche
 
Sivuonthanh Lam
Employment - Genentech/Roche
Stock and Other Ownership Interests - Genentech/Roche
 
Fairooz F. Kabbinavar
Employment - Genentech/Roche
Stock and Other Ownership Interests - Genentech/Roche
 
Ariel Lopez-Chavez
Employment - Roche/Genentech
Stock and Other Ownership Interests - Roche/Genentech
 
Alan Sandler
Employment - Genentech/Roche
Stock and Other Ownership Interests - Genentech/Roche
 
Stephen V. Liu
Consulting or Advisory Role - ARIAD; Boehringer Ingelheim; Celgene; Genentech; Lilly; Pfizer
Research Funding - Bayer; Clovis Oncology; Corvus Pharmaceuticals; Esanex; Genentech/Roche; Ignyta; MedImmune; Merck; OncoMed; Pfizer; Threshold Pharmaceuticals